Agenda

Alto Neuroscience Overview and Background - Amit Etkin, M.D., Ph.D. - Founder & CEO

Understanding MDD with poor memory - Amit Etkin, M.D., Ph.D. - Founder & CEO

  • Clinician Perspective - Dr. Gerard Sanacora

Mechanism of ALTO-100 & Link to Patient Population - Amit Etkin, M.D., Ph.D. - Founder & CEO

ALTO-100 Clinical Development
  • Development history - Amit Etkin, M.D., Ph.D. - Founder & CEO
  • Phase 2b clinical study overview - Jessica Powell - Chief Development Officer
  • Baseline characteristics - Adam Savitz, M.D., Ph.D. - Chief Medical Officer

Commercialization Considerations - Michael Hanley - Chief Operating Officer
  • Overview of cognition biomarker data - audience performance

Expert Perspective - Gerard Sanacora, Ph.D. M.D. -- George D. and Esther S. Gross Professor of Psychiatry, Director of Yale Depression Research Program, Yale University

Question & Answer - All